Breast cancer research
Medica Scientia Innovation Research S.L. concentrates much of its clinical research activity on advanced breast cancer, with particular attention to triple-negative breast cancer, hormone receptor-positive disease, HER2-positive disease, and HER2-low and HER2-ultralow subtypes. Its studies also include early-stage breast cancer, metastatic breast cancer, and biologically defined groups such as ESR1-mutated, PIK3CA-mutated, and PTEN-altered tumors.
- Triple-negative breast cancer
- HER2-positive and HER2-low breast cancer
- Hormone receptor-positive breast cancer
- Early breast cancer
- Metastatic breast cancer
The portfolio also includes research in metaplastic breast cancer, aggressive disease settings, and breast tumors with distinct molecular features that guide treatment selection.
Central nervous system and brain metastasis studies
A major therapeutic interest lies in cancers involving the central nervous system, especially brain metastases and leptomeningeal disease. These studies span metastatic breast cancer, non-small cell lung cancer, and other solid tumors with intracranial spread or neurologic involvement.
- Brain metastases
- Leptomeningeal disease
- Intracranial response
- Neurologic metastatic involvement
- Solid tumors with CNS spread
Research in this area includes tumors with active or progressing intracranial disease, reflecting a focus on difficult-to-treat metastatic patterns affecting the brain and meninges.
Lung cancer and thoracic malignancies
The sponsor funds studies in non-small cell lung cancer, including cases with ROS1-positive disease and active brain metastasis. Its thoracic oncology interests also extend to thymic carcinoma and B3-thymoma, broadening its work across uncommon and advanced thoracic malignancies.
- Non-small cell lung cancer
- ROS1-positive lung cancer
- Brain metastatic lung cancer
- Thymic carcinoma
- B3-thymoma
These trials reflect interest in both molecularly selected lung cancer populations and rarer thoracic tumors requiring specialized treatment approaches.
Hormone-driven and genomically selected cancers
Clinical research also covers hormone receptor-positive breast cancer and metastatic hormone-naïve prostate cancer, with attention to tumors defined by ESR1, PIK3CA, and PTEN alterations. These studies emphasize endocrine-sensitive and endocrine-resistant disease contexts.
- ER-positive breast cancer
- ESR1-mutated advanced breast cancer
- PIK3CA-altered breast cancer
- PTEN-altered breast cancer
- Metastatic hormone-naïve prostate cancer
The sponsor’s portfolio includes tumors with endocrine resistance and biomarker-defined subgroups, supporting research in targeted treatment selection for hormonally driven malignancies.
Ovarian cancer and other solid tumors
Additional research activity includes ovarian cancer with oligometastatic progression and selected advanced solid tumors with metastatic complications. The portfolio also reaches beyond breast and thoracic oncology to address complex disease settings requiring systemic treatment strategies.
- Ovarian cancer
- Oligometastatic progression
- Advanced solid tumors
- Metastatic disease
- Systemic therapy research
These studies add breadth to the sponsor’s oncology portfolio, with attention to recurrent and metastatic disease across multiple tumor types.
